

A New Level of Clarity to Accelerate Clinical Trials

Intelligence ▶ Technology ▶ Expertise



Who We Are

We are a leading provider of intelligent technology, insights and expertise that reduce the barriers and time involved in designing and conducting clinical trials and research, from feasibility and site selection to patient screening and matching. We harness vast sets of oncology and patient data to bring a new level of clarity to the process—opening more opportunities for patients and accelerating scientific discoveries.

Our Solutions

Our solutions help CROs Accelerate clinical trials, improve feasibility and support business development activities through a powerful combination of the Inteliquet Real World Data Asset and technology platform.

The Inteliquet software platform

Powerful software to conduct optimal feasibility, site selection and faster, more accurate patient screening and matching.

Predictive analytics and insights

Enhanced intelligence, real-world evidence and longitudinal data for optimal decision, outcomes and increased patient accrual rates.

The clinical consortium

The Fastest-growing Patient Data Consortium, providing a robust Real-world data asset and a new level of clarity and accuracy to identify eligible patients for complex clinical trials, particularly for oncology.

40%
greater
accrual
rates

reported with
Inteliquet,
especially for
hard-to-enroll
trials.

Our Core Capabilities

- ▶ Vast oncology data consortium allows access to Rx, therapies, Labs, molecular biomarkers, visit data, diagnoses, histology, outcomes
- ▶ Improve efficiency in trial site identification and selection, patient enrollment
- ▶ Robust and expanding oncology practice network, including community, hospitals, and academic medical centers
- ▶ Large Real-world Data asset
 - ▶ Real-time patient and population data
 - ▶ Real-world evidence, in real-time, to quickly identify eligible patients for trials, feasibility and gain visibility into treatment patterns
- ▶ Superior data quality and completeness



The Inteliquet Clinical Consortium

4.7+ million
patients

1.2+ million
cancer patients

86+ million
treatment details

- ▶ Millions of patients sorted by diagnoses, treatment details, outcomes, and biomarkers.
- ▶ Hundreds of participating providers at leading U.S. healthcare institutions.
- ▶ Access to a portfolio of hundreds of funded studies directly from our partners.
- ▶ Works seamlessly and securely with different EHR systems.
- ▶ Rapid, accurate, predictive knowledge supports most promising care to patients.

Scientific Advisory Board

We work with some of the top minds and thought leaders across many areas of oncology, translational research and genomics, and pathology. Our Scientific Board helps guide our mission, vision and strategies and ensures we are bringing the best to bear to providers, researchers and patients everywhere.

Barbara McAneny, MD, ASCO, MACP

President, American Medical Association (AMA)

Daniel D. Von Hoff, MD, FACP

Physician in Chief, Distinguished Professor of the Translational Research Division at TGen (Translational Genomics Research Institute)

Paul A. Bunn, Jr., MD

Distinguished Professor of Medicine and the James Dudley endowed Professor of Lung Cancer research at the University of Colorado Cancer Center and School of Medicine

Noah M. Hahn, MD

Associate Professor of Medicine at the Department of Oncology and the Department of Urology at Johns Hopkins University School of Medicine

Stanley R. Hamilton, MD, FACP, AGAF

Professor and Head of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center (UTMDACC)

W Jeff Edenfield, MD

Greenville Health System Institute for Translational Oncology Research

Patients First

We believe that every patient deserves access to a clinical trial. Clinical trials have the potential to save and extend lives, improve the standard of care, and ultimately find lasting solutions for cancer and other critical diseases. That's what drive us—every day we help ensure no patient goes without access to a clinical trial thus accelerating the availability of promising new treatments.

Contact us

info@inteliquet.com • inteliquet.com

